Approach and Management of Dizziness and Bradycardia
For patients presenting with dizziness and bradycardia, immediately assess hemodynamic stability and symptom severity—if hemodynamically unstable or severely symptomatic, administer atropine 0.5-1 mg IV and prepare for temporary pacing; if stable, evaluate for reversible causes before considering permanent pacemaker implantation. 1
Initial Assessment and Risk Stratification
The critical first step is determining whether the patient is hemodynamically stable or unstable. Look specifically for:
- Hemodynamic compromise: Hypotension, altered mental status, chest pain, acute heart failure
- Symptom severity: Syncope, near-syncope, severe dizziness versus mild lightheadedness
- ECG findings: Heart rate, presence of pauses, type of bradyarrhythmia (sinus node dysfunction vs. AV block)
Most patients with sinus node dysfunction present with chronic complaints and are stable, requiring no acute intervention 1. However, the presence of dizziness warrants careful evaluation as it may indicate cerebral hypoperfusion 2, 3.
Acute Management for Symptomatic/Unstable Patients
Pharmacologic Therapy
For symptomatic bradycardia with hemodynamic compromise, atropine is the first-line agent (Class IIa recommendation) 1:
- Dose: 0.5-1 mg IV, repeat every 3-5 minutes up to maximum 3 mg
- Mechanism: Blocks parasympathetic input to increase sinus rate
If atropine is ineffective or contraindicated (e.g., post-heart transplant patients—where atropine should NOT be used), consider beta-agonists 1:
- Isoproterenol: 20-60 mcg IV bolus or 1-20 mcg/min infusion
- Dopamine: 5-20 mcg/kg/min IV starting at 5 mcg/kg/min
- Epinephrine: 2-10 mcg/min IV or 0.1-0.5 mcg/kg/min IV
Important caveat: Beta-agonists carry a Class IIb recommendation and should only be used in patients at low likelihood of coronary ischemia due to risk of precipitating ischemia 1.
Temporary Pacing
For persistent hemodynamically unstable bradycardia refractory to medical therapy, temporary transvenous pacing is reasonable (Class IIa) 1:
- Preferred over transcutaneous pacing for sustained support
- Transcutaneous pacing may be considered as a bridge (Class IIb) but is painful and less reliable
- Do NOT pace patients with minimal/infrequent symptoms without hemodynamic compromise (Class III: Harm) 1
Evaluation for Reversible Causes
Before rushing to permanent pacemaker implantation, systematically evaluate for potentially reversible etiologies 1:
Medications
- Beta-blockers, calcium channel blockers, digoxin, antiarrhythmics
- Consider withdrawal if clinically appropriate
Metabolic/Endocrine
Cardiac
Other Critical Causes
- Increased intracranial pressure 4
- Infections 1
- Sleep apnea-hypopnea syndrome: This is a commonly missed reversible cause 5. In patients with obesity, daytime tiredness, and symptomatic bradycardia, screen for sleep apnea before pacemaker implantation. Treatment with nCPAP can resolve bradycardia and obviate need for pacing 5.
- COVID-19 infection (emerging recognition) 6
Diagnostic Workup for Stable Patients
For stable patients, evaluation can proceed in the outpatient setting 1:
- 12-lead ECG: Document bradyarrhythmia type (sinus node dysfunction vs. AV block) 3, 7
- Holter monitoring: Essential for intermittent bradycardia 3
- Laboratory tests: TSH, electrolytes, troponin, complete blood count
- Echocardiography: Assess structural heart disease
- Medication review: Identify offending agents
Long-Term Management
When to Implant a Permanent Pacemaker
The 2018 ACC/AHA/HRS guidelines shifted emphasis from device-based recommendations to comprehensive evaluation and management 7. Permanent pacing is indicated for symptomatic bradycardia when reversible causes have been excluded or treated 1.
Special Considerations
Vagal-mediated bradycardia: These are generally benign and do not require pacing 8. Careful ECG interpretation is needed to distinguish intrinsic conduction system disease from extrinsic vagal influences.
Post-spinal cord injury: Bradycardia may be refractory to atropine; consider aminophylline or theophylline as these target unopposed parasympathetic stimulation 1.
Common Pitfalls to Avoid
- Implanting a pacemaker without screening for sleep apnea in obese patients with daytime somnolence 5
- Using atropine in heart transplant patients without autonomic reinnervation (Class III: Harm) 1
- Pacing minimally symptomatic patients without hemodynamic compromise (Class III: Harm) 1
- Missing medication-induced bradycardia that resolves with drug withdrawal
- Failing to document the bradyarrhythmia with ECG monitoring before making treatment decisions 3